Samotolisib
CAS: 1386874-06-1
Ref. 3D-LFC87406
| 5mg | To inquire | |
| 10mg | To inquire | |
| 25mg | To inquire | |
| 50mg | To inquire | |
| 100mg | To inquire |
Product Information
Samotolisib is a novel drug that has been shown to inhibit tumor growth in vivo. Samotolisib was effective against tumors in a mouse xenograft model, as well as against both skin and bone cancer in mice. The molecular docking analysis suggests that samotolisib binds to the ATP-binding site of the enzyme ribonucleotide reductase (RNR), thereby inhibiting the production of DNA precursors required for protein synthesis. This inhibition leads to apoptosis and necrosis of tumor cells. Samotolisib has also been shown to induce autophagy and apoptosis in cultured human skin cells, suggesting it may have potential for treating skin cancers.
Chemical properties
Technical inquiry about: 3D-LFC87406 Samotolisib
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
